Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Closed 06-08 16:00:00 EDT

30.80

-0.31

-1.00%

盘后30.80

+0.000.00%

17:01 EDT

High31.69	Low30.59	Vol1.02M
Open31.67	D1 Closing31.11	Amplitude3.54%
Mkt Cap6.32B	Tradable Cap2.74B	Total Shares205.31M
T/O31.38M	T/O Rate1.14%	Tradable Shares89.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":30.8,"timestamp":1780948800000,"preClose":31.11,"halted":0,"volume":1015711,"hourTrading":{"tag":"盘后","latestPrice":30.8,"preClose":30.8,"latestTime":"17:01 EDT","volume":22608,"amount":704563.49,"timestamp":1780952505202,"change":0,"changeRate":0,"amplitude":0.032468},"delay":0,"changeRate":-0.009964641594342615,"floatShares":89017500,"shares":205308917,"eps":-2.77164,"marketStatus":"Closed","change":-0.31,"latestTime":"06-08 16:00:00 EDT","open":31.67,"high":31.69,"low":30.59,"amount":31379873.332390003,"amplitude":0.035358,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.77164,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780992000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":31.11,"preHourTrading":{"tag":"盘前","latestPrice":31.65,"preClose":31.11,"latestTime":"09:29 EDT","volume":3568,"amount":112011.0268,"timestamp":1780925399999,"change":0.54,"changeRate":0.017358,"amplitude":0.019929},"postHourTrading":{"tag":"盘后","latestPrice":30.8,"preClose":30.8,"latestTime":"17:01 EDT","volume":22608,"amount":704563.49,"timestamp":1780952505202,"change":0,"changeRate":0,"amplitude":0.032468},"volumeRatio":0.665504,"impliedVol":0.5789,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/IMVT","defaultTab":"news","newsList":[{"id":"2641179545","title":"Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641179545","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641179545?lang=en_us&edition=fundamental","pubTime":"2026-06-08 01:13","pubTimestamp":1780852390,"startTime":"0","endTime":"0","summary":"Recent commentary on Immunovant’s IMVT-1402 program highlighted high response rates in a completed Phase 2 rheumatoid arthritis trial, including in patients who had already received multiple advanced therapies.\nThis focus on difficult-to-treat patients has pushed IMVT-1402 to the center of Immunovant’s story, raising questions about how such response rates could shape expectations for its broader autoimmune pipeline.\nWe’ll now look at how the strong IMVT-1402 Phase 2 responses in difficult...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","IMVT","RA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639260672","title":"Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2639260672","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639260672?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:05","pubTimestamp":1780085153,"startTime":"0","endTime":"0","summary":"Immunovant director Andrew J. Fromkin sold 221,951 shares on May 28, 2026 at weighted-average prices of $32.64 and $33.56.He exercised stock options for 196,601 shares the same day at exercise prices ranging from $4.99 to $14.7.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL1j1p0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4588","BK4007","BK4585","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639671598","title":"Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2639671598","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639671598?lang=en_us&edition=fundamental","pubTime":"2026-05-30 00:06","pubTimestamp":1780070776,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) has been drawing attention after recent share price moves, with the stock up about 24% over the past month and about 21% over the past 3 months, prompting closer scrutiny from biotech investors.\nSee our latest analysis for Immunovant.\nAt the current share price of US$33.50, Immunovant’s recent 30 day share price return of 24.12% and year to date share price return of 29.29% sit alongside a 1 year total shareholder return of 124.98%. This indicates strong momentum over both...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-recent-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638642517","title":"Immunovant Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638642517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638642517?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:06","pubTimestamp":1779800760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 09:06 ET (13:06 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515256","title":"H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515256","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515256?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:37","pubTimestamp":1779791861,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Immunovant, with a price target of $40.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347691","title":"Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347691","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347691?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:26","pubTimestamp":1779488781,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker reported the sale of 200,000 common shares on May 22 at a weighted average price of $30.27.He also exercised stock options for 200,000 common shares on May 22 at $3.85.Venker disposed of 34,483 common shares on May 20 at $32.41.He held 1,613,063 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8bLkBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4007","BK4585","ROIV","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343745","title":"Immunovant Is Maintained at Hold by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343745","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637343745?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:51","pubTimestamp":1779465060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2026 11:51 ET (15:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637430310","title":"Immunovant price target raised to $30 from $23 at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2637430310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637430310?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:20","pubTimestamp":1779459605,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill raised the firm’s price target on Immunovant (IMVT) to $30 from $23 and keeps a Hold rating on the shares. The firm i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-30-from-23-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-30-from-23-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637514393","title":"Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2637514393","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637514393?lang=en_us&edition=fundamental","pubTime":"2026-05-22 14:00","pubTimestamp":1779429657,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. (IMVT) has disclosed a new risk, in the Employment / Personnel category. Immunovant, Inc. faces a material human capital risk, as ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunovants-talent-crunch-how-human-capital-risks-could-derail-imvt-1402-development-across-six-indications?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunovants-talent-crunch-how-human-capital-risks-could-derail-imvt-1402-development-across-six-indications?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637135895","title":"These Analysts Increase Their Forecasts On Immunovant After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2637135895","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637135895?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:07","pubTimestamp":1779379634,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&amp;D expenses rose to $142.3 million. Analysts adjust price targets.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52723743/these-analysts-increase-their-forecasts-on-immunovant-after-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","IMVT","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336545","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Anteris Technologies Global Corp. (AVR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637336545?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:40","pubTimestamp":1779367239,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT), Immunovant (IMVT) and Anteris Technologies Globa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-medtronic-mdt-immunovant-imvt-and-anteris-technologies-global-corp-avr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-medtronic-mdt-immunovant-imvt-and-anteris-technologies-global-corp-avr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089283258.USD","IE00BVYPNW00.USD","XLV","IE000M9KFDE8.USD","LU0106261372.USD","HCSG","LU2111349929.HKD","IE00B3T34201.USD","LU0320765489.SGD","IE00BQXX3D17.EUR","LU0122379950.USD","LU2028103732.USD","LU0158827948.USD","LU1116320901.HKD","XBI","LU1983299246.USD","LU0211326839.USD","LU0128526141.USD","LU0211326755.USD","LU0976567544.SGD","LU1023059063.AUD","LU0265550359.USD","IE00B3PB1722.GBP","AVR","LU0265550946.USD","LU1989771016.USD","LU2271345857.HKD","LU1244550494.USD","BK4585","LU1057294990.SGD","BK4588","IMVT","IE00BFXG1179.USD","LU1506573853.SGD","LU1571399168.USD","BK4137","LU2089984988.USD","BK4082","LABU","IE00BGHQF631.EUR","LU1244550577.SGD","IE00BDGV0183.EUR","LU0496365809.HKD","LU0006306889.USD","MDT","LU0029874061.USD","LU0072461881.USD","LU1061106388.HKD","IE00BQXX3F31.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637513336","title":"Immunovant (IMVT) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2637513336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637513336?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:39","pubTimestamp":1779367191,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant today and set a price target of $45.00. According to TipRanks, Slutsky is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunovant-imvt-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637335586","title":"Assessing Immunovant (IMVT) Valuation After Strong IMVT-1402 Data And Refocused Pipeline Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2637335586","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637335586?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:33","pubTimestamp":1779363214,"startTime":"0","endTime":"0","summary":"Immunovant (IMVT) is back in focus after Week 16 data for its IMVT-1402 rheumatoid arthritis trial showed strong response rates in difficult cases, and its latest earnings report highlighted ongoing losses and funding for continued development.\nSee our latest analysis for Immunovant.\nThe latest IMVT-1402 update has shifted attention firmly to Immunovant’s pipeline, with a 1-day share price return of 35.26% helping push the stock to a 1-year total shareholder return of 144.23%, signaling...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-imvt-1402-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/assessing-immunovant-imvt-valuation-after-strong-imvt-1402-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637338533","title":"Immunovant Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2637338533","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637338533?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:22","pubTimestamp":1779362520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 07:22 ET (11:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637384508","title":"Immunovant, Inc. : H.c. Wainwright Raises Target Price to $40 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2637384508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637384508?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:04","pubTimestamp":1779357840,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nAZN4SXNGO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637038906","title":"Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637038906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637038906?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:26","pubTimestamp":1779355581,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila reiterated a Buy rating on Immunovant yesterday and set a price target of $45.00. The company’s shares closed yes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-immunovant-imvt-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-immunovant-imvt-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637802730","title":"U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2637802730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637802730?lang=en_us&edition=fundamental","pubTime":"2026-05-21 14:42","pubTimestamp":1779345750,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NvidiaMay 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Analog Device","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5d07a255fa50ca2b85b03d26b4c3c2c1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nL4N41Y0I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANV","KO","07388","2NVD.UK","KEYS","GLGG","NVDU","IE00B4YYXB79.USD","GTM","07788","LOW","NVII","NVD3.UK","NVDW","DIPS","NVDA","NVDS.UK","NVIW.SI","SXTP","INTU","NVDS","SNVD.UK","NVDX","NVYY","NVDG","LU1548497426.USD","COR","NVDQ","NVDL","NVDB","TGT","ELF","IE00B19Z9P08.USD","NVDO","IMVT","FLYW","GLXY","SG9999014567.USD","NVD","TOL","TJX","HK0000304797.USD","NVDY","LU0124384867.USD","3NVD.UK","GLXU","NVD2.UK","ADI","HPE","NVDD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637877037","title":"Immunovant director Atul Pande disposes 6,000 shares for $192,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2637877037","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637877037?lang=en_us&edition=fundamental","pubTime":"2026-05-21 09:22","pubTimestamp":1779326554,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande reported selling 6,000 common shares at USD 32 on May 20, 2026.The sale followed the exercise of 6,000 stock options at USD 8.43 per share on the same day.Pande’s direct common share holdings fell to 116,731 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLbXDHhV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4585","IMVT","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637244988","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637244988","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637244988?lang=en_us&edition=fundamental","pubTime":"2026-05-21 01:40","pubTimestamp":1779298822,"startTime":"0","endTime":"0","summary":"Immunovant  said Wednesday its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.Shares climbed more than 33%, with intraday trading volume rising to over 14.8 million from a daily average of roughly 1.4 million.Dorian LPG  shares jumped 12% amid heavy trading after the company reported a year-over-year surge in fiscal Q4 adjusted earnings and revenue on Wednesday.More than 1.16 million shares of the company traded intraday compared with a daily average of about 523,000.Price: 35.17, Change: +8.88, Percent Change: +33.77","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LPG","BK4139","BK4588","IMVT","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637026821","title":"Immunovant Stock Surges Despite Disappointing Earnings Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2637026821","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637026821?lang=en_us&edition=fundamental","pubTime":"2026-05-21 01:09","pubTimestamp":1779296946,"startTime":"0","endTime":"0","summary":"Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3a8b9766ee9af93acdd4c2a16a2c1acc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/05/52699085/immunovant-stock-surges-despite-disappointing-earnings-miss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":-0.0658},{"period":"1month","weight":0.0851},{"period":"3month","weight":0.1669},{"period":"6month","weight":0.3621},{"period":"1year","weight":0.9419},{"period":"ytd","weight":0.2238}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.068522},{"month":7,"riseRate":0.571429,"avgChangeRate":0.040449},{"month":8,"riseRate":0.571429,"avgChangeRate":0.080342},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction